Magnetic Resonance Imaging Assessment of Morphological Changes and Molecular Behavior to Evaluate Treatment Response of Brain Metastatic Lesions After Stereotactic Radiosurgery.

Background: Brain metastases (BMs) are the most common type of intracranial tumors, frequently arising from primary cancers such as lung, breast, melanoma, and renal cell carcinoma. Magnetic resonance imaging (MRI) plays a crucial role in assessing both the morphological and molecular characteristics of BMs, particularly in evaluating treatment response following radiosurgery. However, the interpretation of these imaging changes remains complex, often influencing clinical decision-making.

Unveiling the Rare: A Case of Renal Cell Carcinoma Acrometastasis.

Acrometastasis refers to a rare form of skeletal metastasis affecting sites distal to the knees and elbows, often leading to significant functional impairment and reduced quality of life. This case report details a 65-year-old man with a history of renal cell carcinoma (RCC) who presented with persistent pain and swelling in the distal aspect of his left long finger. An incisional biopsy confirmed the lesion as metastatic RCC.

Renal Cell Carcinoma Presenting As Isolated Malignant Pleural Effusion: A Case Report.

Renal cell carcinoma (RCC) of the clear cell type is the most common form of renal malignancy. Malignant pleural effusion (MPE) as the initial presentation of RCC is very rare. This case report presents a case of RCC that initially manifested as a pleural effusion, without the typical symptoms of flank pain, hematuria, or a palpable abdominal mass.

Evaluation of the safety, biodistribution, dosimetry of [F]AlF-NYM005 and initial experience in clear cell renal cell carcinoma: an interim analysis of a prospective trial.

Purpose: This first-in-human study aimed to evaluate the radiation dosimetry and whole-body biodistribution of [F]AlF-NYM005, a novel small-molecule carbonic anhydrase IX (CAIX) targeting agent, and to investigate its ability to detect CAIX-positive tumors using PET scans in a cohort of clear cell renal cell carcinoma (ccRCC) patients.

Methods: [F]AlF-NYM005 was synthesized using a fully automatic cassette module Mortenon M1 (Nuoyu, China). Thirty-five patients with a suspicious lesion considered primary renal malignancy or a history of ccRCC were prospectively recruited and studied.

Development of a centrosome amplification-associated signature in kidney renal clear cell carcinoma based on multiple machine learning models.

Background: Centrosome amplification (CA) has been shown to be capable of initiating tumorigenesis with metastatic potential and enhancing cell invasion. We were interested in discovering how centrosome amplification-associated signature affects the prediction of prognosis and response to therapy in kidney renal clear cell carcinoma (KIRC).

Methods And Materials: The TCGA-KIRC dataset was used to construct a centrosome amplification-associated signature using the random survival forest analysis and Cox regression analysis, and the ICGC and GEO datasets were employed for signature validation.

Clinical implications of tumor laterality in renal cell carcinoma.

Introduction: It is unclear whether laterality has prognostic implications for patients with renal cell carcinoma (RCC). Some suggest that left sided tumors may have worse survival outcomes. The purpose of this study is to associate tumor characteristics and clinical outcomes with laterality in patients with RCC.

Kidney cancer: From tumor biology to innovative therapeutics.

Renal cell carcinoma (RCC) constitutes the most frequent kidney cancer of the adult population and one of the most lethal malignant tumors worldwide. RCC often presents without early symptoms, leading to late diagnosis. Prognosis varies widely based on the stage of cancer at diagnosis.

CDC20-Mediated Selective Autophagy Degradation of PBRM1 Affects Immunotherapy for Renal Cell Carcinoma.

Polybromo 1 (PBRM1) inactivating mutations are associated with clinical benefit from immune checkpoint inhibitor treatments in clear cell renal cell carcinoma (ccRCC). However, whether targeting PBRM1 has the potential to enhance immunotherapy efficacy in patients with wild-type PBRM1 and the upstream pathways that regulate PBRM1 protein stability remain unclear. Here, it is demonstrated that PBRM1 knockdown induced M1 macrophage polarization and infiltration, which enhanced the efficacy of anti-PD-1 immunotherapy in RCC.

Aggressive renal cell carcinoma with somatic BRCA2 mutation-an emerging entity? A case report with literature review.

Role of BRCA2 gene mutation in renal tumorigenesis remains largely unclear. There are only two case reports of renal cell carcinoma (RCC) with BRCA2 mutation, both of which showed a high-grade RCC with various architectural patterns including tubulopapillary and solid. The tumor cells were described as having eosinophilic cytoplasm and prominent nucleoli.

On integrative analysis of multi-level gene expression data in Kidney cancer subgrouping.

Kidney cancer is one of the most dangerous cancer mainly targeting men. In 2020, around 430, 000 people were diagnosed with this disease worldwide. It can be divided into three prime subgroups such as kidney renal cell carcinoma (KIRC), kidney renal papilliary cell carcinoma (KIRP) and kidney chromophobe (KICH).

Biomarker analyses from the phase 3 randomized CLEAR trial: Lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma.

Background: In CLEAR, lenvatinib + pembrolizumab (L+P) significantly improved efficacy versus sunitinib in first-line treatment of patients with advanced renal cell carcinoma (RCC). We report results from CLEAR biomarker analyses.

Methods: PD-L1 immunohistochemistry (IHC) and next-generation sequencing assays (whole exome sequencing/RNA-sequencing) were performed on archival tumor specimens.

Deep learning-based prediction of tumor aggressiveness in RCC using multiparametric MRI: a pilot study.

Objective: To investigate the value of multiparametric magnetic resonance imaging (MRI) as a non-invasive method to predict the aggressiveness of renal cell carcinoma (RCC) by developing a convolutional neural network (CNN) model and fusing it with clinical characteristics.

Methods: Multiparametric abdominal MRI was performed on 47 pathologically confirmed RCC patients between 2019 and 2023. Preoperative MRI was performed on all patients to assess their clinical characteristics.

Targeting HIF-2α: the role of belzutifan in clear cell renal carcinoma management.

Introduction: Belzutifan is a first-in-class hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor. It targets the von Hippel-Lindau protein (pVHL)-HIF-vascular endothelial growth factor (VEGF) pathway, which is crucial in cellular responses to hypoxia. By inhibiting HIF-2α, belzutifan disrupts the transcription of genes involved in tumor growth and angiogenesis.

Research on the effect of LAMP1 in the development and progression of ccRCC and its potential mechanism with LC3C-mediated autophagy.

Background: Lysomembrane-associated protein 1 (LAMP1), known to exhibit differential expression in various tumor types and play a crucial role in the development of tumors. Clear cell Renal Cell Carcinoma (ccRCC) is still the most common pathological type of renal carcinoma with poor prognosis. However, the expression of LAMP1 and its underlying molecular mechanism with ccRCC remain elusive.

DHX34 as a promising biomarker for prognosis, immunotherapy and chemotherapy in Pan-Cancer: A Comprehensive Analysis and Experimental Validation.

As a member of the DExD/H-box RNA helicase family, DHX34 has demonstrated a significant correlation with the development of multiple disorders. Nevertheless, a comprehensive investigation between DHX34 and pan-cancer remains unexplored. We analyzed the value of DHX34 in pan-cancer based on some databases, such as The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and The Human Protein Atlas (HPA) by use the R language as well as some online analysis tools, including STRING, TISIDB, TISCH2.

Impact of Treatment Strategies on Survival and Within Multivariate Predictive Model for Renal Cell Carcinoma Based on the SEER Database: A Retrospective Cohort Study.

Background: This project aims to shed light on how various treatment approaches affect RCC patients' chances of survival and create a prediction model for them.

Methods: Data from the Surveillance, Epidemiology, and End Results database were used in this investigation. OS and RCSS after radiation, chemotherapy, and surgery were investigated using the Kaplan-Meier approach.

Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis of Individual Patient Data.

Background And Objective: The role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) in the era of immune checkpoint inhibitors (ICIs) is controversial. We aimed to investigate the survival benefit of CN in patients with mRCC treated with ICIs.

Methods: We searched the EMBASE, MEDLINE, and Web of Science databases up to August 26, 2023 to identify studies comparing overall survival (OS) for patients with mRCC treated with ICIs with or without CN.

The Upper TRACT Endometry Score: development and internal validation of an objective measure of variables that impact endoscopic procedures for upper tract urothelial carcinoma.

Purpose: Endoscopic management (EM) is an increasingly accepted option for upper tract urothelial carcinoma (UTUC). Feasibility can be dependent on a variety of variables. The objective of this study was to identify anatomic and phenotypic tumor characteristics that impact EM, using structured expert forecasting, develop and obtain consensus on an assessment score, and perform initial validation of the score in a retrospective database.